Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Lifemine Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://lifeminetx.com/
Year Founded: 2017
Status: Private
BioCentury | Aug 27, 2024
Emerging Company Profile
Montai: Mapping chem-bio connections to find human-vetted therapies
Flagship company uses in silico screening to mine ‘Anthromolecules’ as starting points for pills targeting well-validated pathways, with an initial focus on I&I
BioCentury | Aug 18, 2023
Management Tracks
CSL names first chief sustainability officer
Plus: Jones hired as CCO at NewAmsterdam, and updates from Foresight, Kronos, Antheia and more
BioCentury | Mar 30, 2023
Management Tracks
Former J&J exec Mammen sees ‘long-lived’ biotech, succeeds Verdine at Fog
Seeing ‘meaningful’ medicines in pipeline, the Theravance and pharma vet jumps to a well-funded biotech, taking the reins from a leader he knows well
BioCentury | Dec 7, 2022
Management Tracks
Bill Meury to lead Karuna
Plus: Moore to head Roche Diagnostics North America division, and updates from Agios, Verge, LifeMine and more
BioCentury | Oct 6, 2022
Management Tracks
LifeMine rounds out team with Stahl, Plamondon
Plus Theolytics adds Actelion vet Oakley as CFO, and updates from Capricorn, Cambrian,
BioCentury | Mar 23, 2022
Deals
Mining fungal genomes, LifeMine plots future with $175M series C, GSK partnership
Sourcing new drugs from fungal library, LifeMine team including Verdine, Klausner and Zhou raises megaround, lands first major pharma partner
BioCentury | Dec 9, 2021
Management Tracks
Wilson joins gene therapy play Rocket
Plus updates from Tessera, Oramed, Ikena and more
BioCentury | Jan 13, 2021
Emerging Company Profile
LifeMine taps fungal genomes for new drug candidates
Emerging Company Profile: Start-up led by Klausner and Verdine seeking drug candidates with new mechanisms
BioCentury | Jun 29, 2018
Product R&D
Highly personal
Why GV and Canaan backed Pact Pharma’s hyperpersonalized cancer approach
BioCentury | Sep 28, 2017
Product R&D
Wave’s purity progress
Wave reveals how it makes its stereopure oligos
Items per page:
1 - 10 of 13